Punit

Vaccine Characteristics | Dengue Serotypes | Efficacy & Side-Effects The Global Dengue Vaccine Landscape & Characteristics 📸1: DengiALL (Preclinical Study) - Successful In the Rhesus Monkey challenge study - conducted by NIH, USA against all 4 Dengue serotypes. (Ref: Panacea Biotec) 📸2: DengiALL (Clinical Study) - Early clinical data from Phase I/ll trials in healthy Indian adults showed that a single dose generated strong immunogenicity against all 4 serotypes, while maintaining a favorable safety profile. Qdenga Limitations (Efficacy & Side-Effects) 📸3: Dengue is caused by 4 serotypes (DENV-1 to DENV-4). While TAK-003 (Qdenga) is highly effective against DENV-2 (its genetic backbone), its efficacy is notably lower against DENV-3 and DENV-4 📸4: Other Dengue Vaccines & Qdenga Age group related side-effects Dengvaxia®: Production is being discontinued in 2026. Qdenga®: In clinical studies, the most frequently reported reactions in subjects aged 6 to 45 years of age were injection site pain (54%), headache (36%), myalgia (34%), injection site erythema (29%), malaise (24%), asthenia (21%) and fever (10%)

Kerendia | CKD & Heart Failure | Expanded Indications Kerendia Approval's - Heart Failure & a LVEF of ≥40% 📸1: April 2026 (UKMHRA) - Bayer receives UKMHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40% 📸1: March 2026 (EU) - Kerendia® is approved in the EU for a new indication in adult patients with heart failure & a LVEF of ≥40% Kerendia Treatment Approach & Sales 📸3: HF is a complex disease with major differences in each subtype requiring different treatment approaches 🫀HFmrEF (LVEF 41%-49%) 🫀HFpEF (LVEF ≥50%) 📸4: Kerendia demonstrated accelerated sales momentum in CKD/T2D, now FDA approved for HF LVEF≥40%

Companion Animal | Parasiticides | Isoxazoline Combo 📸1a: US Canine Parasiticides Potential Addressable Market 📸1b: US Dogs on an Isoxazoline Combo 📸2: Expected Parasiticide Market Growth ($B)

ADC Growth | Oncology Therapy | HER2 Biomarker 📸1: Dishman on ADCs growth & Oncology Sales Growth (Ref: Dishman Carbogen) 📸2: HER2 status epidemiology in Breast Cancer (Ref: Daiichi Sankyo)

Animal Health | One R&D | Human Health 📸1: R&D Synergy R&D group dedicated to supporting CMO/CDMO partners R&D teams to be co-located; to work collaboratively on NPD & cost improvement 📸2: Manufacturing Synergy Proven capability to handle Iron complex, Inorganic products & complex molecules QA & Testing to be moved on-site from 3rd party location Ref: Viyash Scientific

Td Vaccine | Immunization Program | Tetanus & Adult Diphtheria 📸1: Union Health Minister to launch Tetanus and Adult Diphtheria (Td) Vaccine at CRI, Kasauli on 21st Feb 2026 (Ref: PIB 2026) 📸2: Panacea Biotec is in the process of launching TedShot® (Tetanus and Diphtheria reduced) vaccine in India after having received marketing authorisation in India 📸3: Receipt of Letter of Award from CMSS for supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP (Ref: Panacea Biotec)

Similar MOAs | Nubeqa vs Erleada | Safety & Efficacy 📸1: The time between market entrants has shortened, even within the same MoA 📸2: Nubeqa (Darolutamide) vs Erleada (Apalutamide) Sales (2021 - 2025) - Patient Expansion for Nubeqa 📸2a: Nubeqa FDA Approved July 2019 - Sales growth of Nubeqa between 2021-2025 ~ 968% 📸2b: Erleada FDA Approved Feb 2018 - Sales growth of Erleada between 2021-2025 ~ 177% 📸2c: Efficacy of Darolutamide vs Peer drugs (Ref: Kotak Institutional Equities for Acutaas Chemicals)

APIs & Formulation➡️Merger⬅️Diagnostic Industry 📸1: Scheme of Amalgamation [Meger by Absorption] of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company) 📸2: Kopran an entry into the fast-growing $14 billion Indian diagnostic industry, which is growing at a CAGR of 14% over the next 5 years & is expected to almost double and reach $25 billion in FY'28 and nearly threefold by 2034. Ref: Kopran

Animal Health | Combined Manufacturing | Human Health 📸1: Combined API Manufacturing Network : 10 facilities with global approvals 📸2b: Albendazole (Animal & Human Health) - New production block created and got EU approval; commercialization already started 📸2b: Animal Health R&D : 4 New animal health products developed/validated Ref: Viyash Scientific

Pentavalent | Diphtheria Outbreak | Child Vaccination 📸1: Pentavalent vaccine demand increased by UNICEF 57% in 2024 and 52% in 2025 (Ref: UNICEF/WHO) 📸2: Panacea has established relationships with its key customers i.e. UNICEF and PAHO for supply of pentavalent vaccine to Gavi countries through UNICEF and to PAHO member countries located in Latin America through PAHO (Ref: Panacea Biotec)

TransCon Technologies | Endocrinology Rare Disease | Therapy 📸1: TransCon Clinical Development Pipeline 📸2: SKYTROFA - High Value Growth Hormone Brand 📸3: YORVIPATH is the first and only product indicated for the treatment of hypoparathyroidism in adults Ref: Ascendis Pharma

Gram +ve & Gram -ve | Organism Coverage | Meropenem 📸1: One of the major players in Sterile Carbapenems (Ref: Kopran) 📸2: Meropenem Antibiotic Organism Coverage

bOPV Vaccine | Polio Eradication | Child immunization 📸1: Poliomyelitis Vaccination coverage by year in India 2000 - 57% - (Coverage - India, Polio, 3rd dose) 2024 - 93.5% - (Coverage - India, Polio, 3rd dose) Panacea Biotec - bOPV Supply Tender issued by CMSS, Govt of India Oct'25 - INR 127 cr 📸2: Market volume higher by 0.5 billion doses from 2023, primarily due to high use of oral polio vaccine (OPV) in 2024 Ref: Panacea Biotec & WHO

Focus Areas➡️Companion Animals➡️Human Health 📸1: Viyash Business Focus Areas Companion Animals - Signed exclusive distribution agreement with Boehringer Ingelheim for companion animal products in India Farm Animals - Launching existing products across all core & new markets Human Health - Leveraging manufacturing in India for mature products APIs + CDMOs - Focus on CDMO opportunities 📸2: Cats & Dogs Ownerships in Europe 🐈🐕 Cat Ownership in Europe Surpasses 108 Million – Up by 2.26 Million Dogs in Europe – Nearly 90 Million & Still Growing

Animal Health | APIs & CDMOs | Human Health 📸1: Animal Health - These trends require strong R&D and manufacturing capabilities to capitalize on these trends; Viyash poised to capture these trends Increasing Pet Ownerships Genericization of Animal health 📸2: Human Health - Two mega trends in the API + CDMO segment Ref: Viyash Scientific

bOPV Co-Administration | Polio Eradication | UNICEF Agreement 📸1: In 2024, UNICEF extended its long-term agreements with manufacturers producing bulk in house. It made awards for 2025 to cover expected demand & needs of other countries that procure through UNICEF. In 2025, UNICEF plans to issue a tender for bOPV supply from 2026 through to bOPV 📷2: Global Polio Eradication Strategy Extension 2022-26 to 2029 (Ref: WHO) 📸3: Panacea bOPV Orders from UNICEF & CMSS, Govt of India - Dec 24 to Oct 25 (Ref: Panacea Biotec)

CDMO Projects | Long-Standing Relationships | Global Reach 📸1a: Dishman Diverse mix of Ongoing Projects Early-stage – 69 Late-stage – 12 Commercial Manufacturing – 28 Formulations – 19 📸1b: Late Phase Molecule & Commercial Market Size Late Phase Molecule Market (in $ Mn) Commercialized Molecule Market (in $ Mn) 📸2: Diverse & Long Relationship with Customers Ref: Dishman Carbogen

Animal Health | Albendazole API | Human Health 📸1: Albendazole API - New production block created in short time to improve capacity, productivity and cost of Sequent products 📸2: Manufacturing again we relooked at network optimization - "We completed and one of the most important area, we completed one of the new production line to accommodate. This is basically Albendazole product. You know Albendazole goes for human health as well as Animal Health. Everything till today we were manufacturing at one site. We are trying to segregate into two sites. So, we segregated human health and build new site at Viyash. It's validated and we filed the regulatory" Ref: Viyash Scientific

Paclitaxel | Platinum-Resistant Ovarian Cancers | Formulations & Exports Ovarian Cancers Therapy - Platinum-Resistant 📸1: When ovarian cancer comes back, doctors usually describe it as either platinum-sensitive or platinum-resistant. This depends on how long it has been since you last had chemotherapy with a platinum-based chemotherapy such as carboplatin or cisplatin 📸2: Agents in black boxes are indicated for the treatment of Platinum-resistant ovarian cancer Panacea Apotex Paclitaxel Profit Sharing (USA & Canada) 📸3: Panacea Apotex - Paclitaxel Profit Share Canada & USA

Electrolyte Additives | Specialty Chemicals | CDMO opportunities Electrolyte Additives - Acutaas Chemicals entered the battery chemicals space in 2022 through its subsidiaries Ami Organics Electrolytes limited Semiconductors Business - Acutaas Chemicals entered the semiconductor industry by acquiring a 55% stake in Baba Fine Chemicals (BFC), effective April 1, 2023. Pharma Intermediates - Grow the Innovator business with more focus on CDMO opportunities Ref: Acutaas Chemicals